Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
Riely
Gregory J
GJ
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Pao
William
W
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D004334:Drug Administration Schedule; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib